Pall launches pyrofree sterile, ready-to-use glass vials
The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines.
Pall Life Sciences’ is formally launching its Pyrofree glass vial line for sterile, flexible filling from 2 mL to 20 mL at PDA.
The Pyrofree vials product range is a unique solution providing filling processes with ready-to-use glass vials depyrogenated and sterilized according to industrial operations methods applied in vaccines, biotechnology, and pharmaceutical industries, and in hospitals. The packaging has been specifically designed for the processing of small batches such as clinical and technical lots, orphan drugs or personalized medicines. The Pyrofree vials product range offers a unique opportunity to simplify, facilitate and accelerate the filling of these products.
A pyrogen is defined as any substance that can cause a fever, such as endotoxins. The injection of endotoxins into the blood can cause severe hazard to a patient and in worst case, lead to septic shock. Depyrogenation, or the removal of pyrogens, is therefore a crucial need in the aseptic filling process of parenteral drugs. Primary packaging of injectable drugs is particularly controlled for the absence of pyrogens and any chemical agent which may alter drug substances properties and stability. In this case, sterilization of primary packaging (e.g., by ethylene oxide sterilization) represents a risk of introducing chemical agents into drug substances.
The Pyrofree vials product range addresses these needs thanks to its unique packaging technology, allowing sterilization and depyrogenation of the vials by dry heat in their primary packaging under vacuum. The Pyrofree process results in ready-to-use vials which can be used for the filling of injectable drugs without using washing and depyrogenation equipment from the filling line.
The Pyrofree vials product range consists of Type I clear glass vials of 2 mL, 5 mL, 10 mL and 20 mL, supplied with grey stoppers of 13 mm and 20 mm diameters, made of bromobutyl with Flurotec coating.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance